<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055716</url>
  </required_header>
  <id_info>
    <org_study_id>EVG002N</org_study_id>
    <nct_id>NCT02055716</nct_id>
  </id_info>
  <brief_title>Sulforadex in Healthy Human Males MAD</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Sulforadex® in Healthy Male Subjects Following Daily Dosing for 7 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evgen Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evgen Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and tolerability of multiple doses of Sulforadex® in healthy male
      volunteers over 7 days with qd or bid dosing
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in a randomised, double-blind, placebo-controlled design with
      multiple ascending doses of Sulforadex® administered qd [once daily] or bid [twice daily]) to
      healthy male subjects between 18 to 45 years of age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>7 days</time_frame>
    <description>Safety assessments will include standard laboratory safety tests (haematology, biochemistry, coagulation and urinalysis), vital signs, physical examinations, 12-lead ECG, telemetry and AE monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of sulforaphane</measure>
    <time_frame>time 0, 30 min 1 2 4 8 12 &amp; 24 hrs post dose on days 1,2 &amp; 7</time_frame>
    <description>Plasma sulforaphane concentrations will be measured by LCMS/MS assay.
• Area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>alpha-cyclodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo comparator composed of the same acid resistant HPMC capsules filled with 300mg of alpha cyclodextrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulforadex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg or 300mg size 00 acid resistant HPMC capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulforadex</intervention_name>
    <arm_group_label>Sulforadex</arm_group_label>
    <other_name>Stabilised sulforaphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-cyclodextrin</intervention_name>
    <arm_group_label>alpha-cyclodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is a healthy male of any race aged 18 to 45 years, inclusive, at screening.

          2. Subject has a BMI of 18 - 25 kg/m2 inclusive at screening.

          3. Subjects must agree to use acceptable methods of contraception,

          4. Subjects should not donate sperm from the time of the first administration of
             treatment or study medication until 3 months following administration of the last
             treatment or dose of study medication.

          5. Subjects must be capable of understanding and complying with the requirements of the
             protocol and must have signed the ICF prior to undergoing any study-related
             procedures.

        Exclusion Criteria:

          1. All subjects must refrain from eating brassica vegetables or using brassica containing
             supplements for at least 7 days prior to the drug administration. Brassica vegetables
             include cabbage, cauliflower, horseradish, landcress, Ethiopian mustard, kale, collard
             greens, Chinese broccoli, brussels sprouts, Kohlrabi broccoli, broccoli flower,
             broccoli romanesco, wild broccoli, bok choy, Komatsuna, mizuna, rapini, flowering
             cabbage, Chinese cabbage, Napa cabbage, turnip root, rutabaga, canola/rape seed,
             Siberian kale, wrapped heart mustard cabbage, mustard seed (brown, black, white),
             tatsoi, rocket (arugula), garden cress, water cress, radish, daikon and wasabi.

          2. Subject has a clinically significant disease or any condition or disease that might
             affect drug absorption, distribution or excretion.

          3. Any clinically significant abnormal laboratory, vital signs or other safety findings
             as determined by medical history, physical examination or other evaluations conducted
             at screening or on admission.

          4. ECG abnormalities in the standard 12-lead ECG (at screening) which in the opinion of
             the Investigator is clinically relevant or will interfere with the ECG analysis.

          5. History or current evidence of any clinically relevant cardiovascular, pulmonary,
             hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic,
             neurological, psychiatric, or other disease.

          6. Positive results in any of the serology tests for Hepatitis B Surface Antigen (HbsAg),
             anti Hepatitis core antibody (anti HBc Ig G [and anti HBc IgM if IgG is positive],
             Hepatitis C virus antibodies (anti HCV), and human immunodeficiency virus HIV 1 and 2
             antibodies (anti HIV 1/2).

          7. Confirmed positive results from urine drug screen (amphetamines, benzodiazepines,
             cocaine, cannabinoids, opiates, barbiturates, tricyclic antidepressants and methadone)
             or from the alcohol breath test at screening and on admission (Day -1).

          8. History or clinical evidence of alcohol or drug abuse.

          9. Mentally handicapped.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jörg Täubel, MD FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richmond Pharmacology Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richmond Pharmacology Limited</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2014</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

